J&J’s First-Quarter Sales Grow on Cancer-Drug Strength
The drug and medical-device maker has been working to ensure consistent growth after losing patent protection for its blockbuster Stelara.
- J&J’s first-quarter profit beats estimates even as Stelara sales disappoint CTV News —
- J&J’s first-quarter profit beats estimates even as Stelara sales disappoint The Globe and Mail —
- Johnson & Johnson Non-GAAP EPS of $2.70 beats by $0.02, revenue of $24.06B beats by $450M Seeking Alpha —
- Earnings Snapshot: Johnson & Johnson tops Q1 expectations; boosts full-year outlook and increases quarterly dividend Seeking Alpha —
- Johnson & Johnson in charts: Q1 Innovative Medicine rises 11.2% as DARZALEX leads growth Seeking Alpha —